Source:http://linkedlifedata.com/resource/pubmed/id/10979946
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
2000-10-4
|
pubmed:abstractText |
A prospective multicenter trial of 119 children 1 to 18 years of age with newly diagnosed aplastic anemia (AA) was conducted, comparing treatment using antithymocyte globulin (ATG), cyclosporine (CyA), and danazol (DAN) with or without rhG-CSF (400 microg/m(2), day on days 1-90). All children with very severe AA received rhG-CSF (VSAA group, n = 50). The other children were randomized to receive ATG, CyA, DAN, and rhG-CSF (G-CSF+ group, n = 35) or ATG, CyA, and DAN without rhG-CSF (G-CSF- group, n = 34). After 6 months, the hematologic response rate was 71%, 55%, and 77% in the VSAA group, G-CSF+ group, and G-CSF- group, respectively. There was no difference in the incidence of febrile episodes and documented infections between the G-CSF+ and G-CSF- groups. Bone marrow transplantation (BMT) was attempted in 22 patients in whom initial immunosuppressive therapy (IST; n = 18) failed or in whom a relapse occurred after an initial response (n = 4). Nineteen of the 22 patients are alive and well after a median follow-up of 18 months (range, 3 to 66 months) since BMT. The probability of survival at 4 years was 83% +/- 7% in the VSAA group, 91% +/- 5% in the G-CSF+ group, and 93% +/- 6% in the G-CSF- group. Myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) developed in one patient in each of the three groups; the overall risk for MDS/AML was 3% +/- 2% at 4 years. Because the results of IST were encouraging, it is suggested that children with AA receive IST as first-line therapy if there is no human leukocyte antigen-matched sibling donor.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antilymphocyte Serum,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclosporine,
http://linkedlifedata.com/resource/pubmed/chemical/Danazol,
http://linkedlifedata.com/resource/pubmed/chemical/Estrogen Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Granulocyte Colony-Stimulating...,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents
|
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0006-4971
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
96
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2049-54
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:10979946-Adolescent,
pubmed-meshheading:10979946-Anemia, Aplastic,
pubmed-meshheading:10979946-Antilymphocyte Serum,
pubmed-meshheading:10979946-Child,
pubmed-meshheading:10979946-Child, Preschool,
pubmed-meshheading:10979946-Cyclosporine,
pubmed-meshheading:10979946-Danazol,
pubmed-meshheading:10979946-Drug Therapy, Combination,
pubmed-meshheading:10979946-Estrogen Antagonists,
pubmed-meshheading:10979946-Female,
pubmed-meshheading:10979946-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:10979946-Humans,
pubmed-meshheading:10979946-Immunosuppression,
pubmed-meshheading:10979946-Immunosuppressive Agents,
pubmed-meshheading:10979946-Infant,
pubmed-meshheading:10979946-Male,
pubmed-meshheading:10979946-Treatment Outcome
|
pubmed:year |
2000
|
pubmed:articleTitle |
Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia.
|
pubmed:affiliation |
Japan Childhood Aplastic Anemia Study Group, Nagoya, Japan. kojimas@med.nagoya-u.ac.jp
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study
|